A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis
Stephen A. Harrison, Mustafa R. Bashir, Kyoung Jin Lee, Jennifer Shim-Lopez, Jonathan Lee, Brandee Wagner, Nicholas D. Smith, Hubert C. Chen, Eric J. Lawitz
Dive into the research topics of 'A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis'. Together they form a unique fingerprint.